Edition:
United States

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

13.41USD
18 Jan 2019
Change (% chg)

$1.05 (+8.50%)
Prev Close
$12.36
Open
$12.38
Day's High
$13.51
Day's Low
$12.30
Volume
537,390
Avg. Vol
259,437
52-wk High
$20.85
52-wk Low
$9.51

Latest Key Developments (Source: Significant Developments)

Alder Biopharmaceuticals- Entered Distribution Deal To Offer, Sell From Time To Time Up To $100 Mln Maximum Aggregate Offering Price Of Shares
Friday, 4 Jan 2019 05:52pm EST 

Jan 4 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS- ENTERED DISTRIBUTION DEAL TO OFFER, SELL FROM TIME TO TIME UP TO $100 MILLION MAXIMUM AGGREGATE OFFERING PRICE OF SHARES.  Full Article

Alder Biopharmaceuticals Q3 Loss Per Share $0.91
Monday, 5 Nov 2018 04:08pm EST 

Nov 5 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS® REPORTS THIRD QUARTER 2018 FINANCIAL AND OPERATING RESULTS.Q3 LOSS PER SHARE $0.91.Q3 EARNINGS PER SHARE VIEW $-1.09 -- THOMSON REUTERS I/B/E/S.ALDER BIOPHARMA - BELIEVES CASH, CASH EQUIVALENTS, INVESTMENTS, RESTRICTED CASH WILL BE SUFFICIENT TO MEET PROJECTED OPERATING REQUIREMENTS INTO 2020.AS OF SEPTEMBER 30, 2018, ALDER HAD $484.7 MILLION IN CASH, CASH EQUIVALENTS, INVESTMENTS AND RESTRICTED CASH.  Full Article

Alder Biopharma Q4 Loss Per Share $0.80
Monday, 26 Feb 2018 04:14pm EST 

Feb 26 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS.Q4 LOSS PER SHARE $0.80.‍BIOLOGICS LICENSE APPLICATION (BLA) ON TRACK FOR SUBMISSION IN 2H18​.  Full Article

Alder Announces $250 Million Committed Equity Financing
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER ANNOUNCES $250 MILLION COMMITTED EQUITY FINANCING.ALDER BIOPHARMACEUTICALS INC - INVESTORS TO PURCHASE UP TO $250 MILLION OF NON-VOTING CLASS A PREFERRED STOCK DURING 3-YEAR TERM OF AGREEMENT.ALDER BIOPHARMACEUTICALS INC - TO USE NET PROCEEDS TO FUND PAYMENTS UNDER ALDER'S EUROPEAN PATENT SETTLEMENT.ALDER BIOPHARMACEUTICALS INC - TO ALSO USE PROCEEDS FOR EPTINEZUMAB INFUSION COMMERCIALIZATION-READINESS ACTIVITIES.  Full Article

Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva
Monday, 8 Jan 2018 08:00am EST 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER BIOPHARMACEUTICALS® ENTERS INTO EUROPEAN PATENT SETTLEMENT AND GLOBAL LICENSE AGREEMENT WITH TEVA IN THE FIELD OF ANTI-CGRP-BASED THERAPY.ALDER BIOPHARMACEUTICALS INC - ‍ALDER HAS AGREED TO MAKE AN IMMEDIATE ONE-TIME PAYMENT OF $25 MILLION TO TEVA​.ALDER BIOPHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, ALDER HAS AGREED TO WITHDRAW ITS APPEAL BEFORE EUROPEAN PATENT OFFICE.ALDER BIOPHARMACEUTICALS - UNDER TERMS CO AGREED TO PAY $75 MILLION AT EACH OF TWO SALES-RELATED MILESTONES FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB.ALDER SAYS UNDER TERMS CO AGREED TO PROVIDE CERTAIN ROYALTY PAYMENTS ON NET SALES AT RATES FROM 5% TO 7% FOLLOWING COMMERCIAL LAUNCH OF EPTINEZUMAB.ALDER - UNDER TERMS CO AGREED TO MAKE SECOND ONE-TIME PAYMENT OF $25 MILLION UPON APPROVAL OF BLA FOR EPTINEZUMAB WITH U.S. FDA.  Full Article

Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial
Monday, 8 Jan 2018 07:30am EST 

Jan 8 (Reuters) - Alder Biopharmaceuticals Inc ::ALDER ANNOUNCES EPTINEZUMAB SIGNIFICANTLY REDUCES MIGRAINE RISK MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PIVOTAL PROMISE 2 PHASE 3 TRIAL FOR CHRONIC MIGRAINE PREVENTION.ALDER BIOPHARMACEUTICALS INC - ANNOUNCED THAT EPTINEZUMAB, MET PRIMARY ENDPOINT IN ITS PIVOTAL PHASE 3 PROMISE 2 CLINICAL TRIAL.ALDER BIOPHARMACEUTICALS INC - ‍15% OF PATIENTS HAD NO MIGRAINES FOR A FULL THREE MONTHS​.ALDER BIOPHARMACEUTICALS INC - IN ADDITION, EPTINEZUMAB MET ALL KEY SECONDARY ENDPOINTS WITH VERY HIGH STATISTICAL SIGNIFICANCE.ALDER BIOPHARMACEUTICALS INC - ‍SAFETY AND TOLERABILITY WERE SIMILAR TO PREVIOUSLY REPORTED EPTINEZUMAB STUDIES​.ALDER BIOPHARMACEUTICALS INC - PLANS TO SUBMIT A BLA TO U.S. FDA FOR EPTINEZUMAB IN H2 OF 2018.  Full Article

Alder Biopharmaceuticals Q3 loss per share $0.92
Tuesday, 7 Nov 2017 04:23pm EST 

Nov 7 (Reuters) - Alder Biopharmaceuticals Inc :Alder biopharmaceuticals announces third quarter 2017 financial and operating results.Q3 loss per share $0.92.Q3 earnings per share view $-1.17 -- Thomson Reuters I/B/E/S.Alder Biopharmaceuticals Inc - ‍eptinezumab biologics license application (BLA) submission on track for 2h18​.Alder Biopharmaceuticals Inc - ‍promise 2 pivotal trial completed enrollment and top-line data on track for 1h18​.Alder-Sees available cash & cash equivalents, short-term investments to be sufficient for projected requirements through late 2018/early 2019​‍​.  Full Article

Alder Biopharmaceuticals Q2 loss per share $1.48
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Alder Biopharmaceuticals Inc :Alder Biopharmaceuticals announces second quarter 2017 financial and operating results.Q2 loss per share $1.48.Q2 earnings per share view $-1.61 -- Thomson Reuters I/B/E/S.  Full Article

Alder Biopharmaceuticals says public offering of 15 mln common shares priced at $10 per share
Wednesday, 12 Jul 2017 06:54pm EDT 

July 12 (Reuters) - Alder Biopharmaceuticals Inc :Alder biopharmaceuticals, inc. Prices public offering of common stock.Says public offering of 15.0 million common shares priced at $10.00per share.  Full Article

Alder Biopharmaceuticals announces commencement of public offering of common stock
Tuesday, 11 Jul 2017 04:28pm EDT 

July 11 (Reuters) - Alder Biopharmaceuticals Inc :Alder Biopharmaceuticals, Inc. announces commencement of public offering of common stock.Alder Biopharmaceuticals Inc - Intends to offer and sell, 12.5 million shares of its common stock in an underwritten public offering.Alder Biopharmaceuticals - Intends to use net proceeds from offering, to fund continued development of eptinezumab, among the others.  Full Article